BioSpace article quoting Ali Pashazadeh, Treehill Partners CEO
“The fractured development environment is directly tied to the financial fragility faced by many companies. Early-stage developers in particular often struggle to design the best study based on the limitations of the available data.”
“Improved real-world evidence sharing could shave tens of millions of dollars in the development timelines of new therapies.”
Read the full Biospace article on how data secrecy is stalling progress (not only) in cell and gene therapy: https://www.biospace.com/drug-development/how-data-secrecy-is-stalling-progress-in-cell-and-gene-therapy